The goal of this review is to add valuable information on the use of immunotherapy in NSCLC with actionable alterations in genes including ALK, ROS1, BRAF, c-MET, RET, NTRK, KRAS, and HER2. Epidermal growth factor receptor (EGFR) mutations are not included in this review as they are included in another manuscript by our group which was submitted separately. Here, ALK is linked to non-small cell lung carcinoma.